Impact of Letrozol Supplementation on Pregnancy Outcomes in Frozen Embryo Transfer: A Prospective Cohort Study

Background & Objective: Letrozol may be associated with improved pregnancy outcomes in women undergoing Frozen Embryo Transfer (FET). This study was conducted with aim to assess the effect of Letrozol supplementation on pregnancy outcomes in infertile women.Materials & Methods: This prospective cohort study was conducted on a total of 134 clinically confirmed infertile women undergoing FET. Participants received 2.5 mg of oral Letrozol every 12 hours for five consecutive days as part of their treatment regimen. The primary outcome was clinical pregnancy, while the secondary outcome was miscarriage rate, defined as spontaneous loss before 20 weeks of gestation. All statistical analyses were conducted using Stata software (Version 17.0, StataCorp, College Station, Texas, USA). P<0.05 was considered statistically significant for all analyses.Results: Among the participants, 42 cases (31.3%) achieved clinical pregnancy. Of these pregnancies, 8 cases (19.0%) resulted in miscarriage. Analysis revealed that abnormal endometrial thickness and the presence of over-mature follicles (over 18 mm) were associated with reduced likelihoods of clinical pregnancy.Conclusion: Letrozol supplementation in FET treatment may be associated with improved clinical pregnancy and miscarriage rates. These findings suggest potential benefits of Letrozol in enhancing fertility outcomes during FET. Further studies are warranted to validate these results and optimize treatment strategies for infertility.